{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+placebo&page=2",
    "query": {
      "intervention": "Carbohydrate placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 2040,
    "total_pages": 204,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+placebo&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T08:34:53.483Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01106625",
      "title": "The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Sulphonylruea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 469,
      "start_date": "2010-05",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2013-06-20",
      "last_synced_at": "2026-10-04T08:34:53.483Z",
      "location_count": 37,
      "location_summary": "Huntsville, Alabama • Little Rock, Alaska • Phoenix, Arizona + 34 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Fair Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01106625"
    },
    {
      "nct_id": "NCT03066778",
      "title": "A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Small Cell Lung Cancer (SCLC)"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal saline solution",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 453,
      "start_date": "2017-05-02",
      "completion_date": "2021-09-21",
      "has_results": true,
      "last_update_posted_date": "2022-10-03",
      "last_synced_at": "2026-10-04T08:34:53.483Z",
      "location_count": 27,
      "location_summary": "Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Munster",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03066778"
    },
    {
      "nct_id": "NCT00363376",
      "title": "A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Weight Gain"
      ],
      "interventions": [
        {
          "name": "Zonisamide",
          "type": "DRUG"
        },
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Sugar Pill (placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lindner Center of HOPE",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2008-01",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2012-04-13",
      "last_synced_at": "2026-10-04T08:34:53.483Z",
      "location_count": 1,
      "location_summary": "Mason, Ohio",
      "locations": [
        {
          "city": "Mason",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00363376"
    },
    {
      "nct_id": "NCT00326443",
      "title": "CVD 909 Vi Prime Boost Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Typhoid Fever"
      ],
      "interventions": [
        {
          "name": "CVD 909",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Vi Polysaccharide",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 21,
      "start_date": "2006-02",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2014-05-09",
      "last_synced_at": "2026-10-04T08:34:53.483Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00326443"
    },
    {
      "nct_id": "NCT00840463",
      "title": "Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Hypertension",
        "Heart Failure With Preserved Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "Ambrisentan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 4,
      "start_date": "2009-01",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2020-05-19",
      "last_synced_at": "2026-10-04T08:34:53.483Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00840463"
    },
    {
      "nct_id": "NCT07712653",
      "title": "Effects of Creatine and Carbohydrate Supplementation on Endurance Performance",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Exercise Performance Recovery"
      ],
      "interventions": [
        {
          "name": "Creatine Monohydrate",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Carbohydrate",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Creatine Monohydrate and Carbohydrate",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "placebo solution",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "California Polytechnic State University-San Luis Obispo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 12,
      "start_date": "2026-07-15",
      "completion_date": "2026-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-10-04T08:34:53.483Z",
      "location_count": 1,
      "location_summary": "San Luis Obispo, California",
      "locations": [
        {
          "city": "San Luis Obispo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07712653"
    },
    {
      "nct_id": "NCT05333939",
      "title": "Moringa Supplementation for Improved Milk Output",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breastfeeding"
      ],
      "interventions": [
        {
          "name": "Moringa leaf powder",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "University of Kentucky",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Months and older"
      },
      "enrollment_count": 41,
      "start_date": "2022-05-17",
      "completion_date": "2024-08-03",
      "has_results": false,
      "last_update_posted_date": "2024-10-17",
      "last_synced_at": "2026-10-04T08:34:53.483Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05333939"
    },
    {
      "nct_id": "NCT01327066",
      "title": "Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "QTc Interval"
      ],
      "interventions": [
        {
          "name": "Droxidopa",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chelsea Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 52,
      "start_date": "2011-03",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2012-03-07",
      "last_synced_at": "2026-10-04T08:34:53.483Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01327066"
    },
    {
      "nct_id": "NCT04109066",
      "title": "Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "paclitaxel (PTX)",
          "type": "DRUG"
        },
        {
          "name": "nivolumab placebo",
          "type": "OTHER"
        },
        {
          "name": "anthracycline",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Endocrine Therapy",
          "type": "DRUG"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 521,
      "start_date": "2019-11-18",
      "completion_date": "2023-12-27",
      "has_results": true,
      "last_update_posted_date": "2025-01-08",
      "last_synced_at": "2026-10-04T08:34:53.483Z",
      "location_count": 30,
      "location_summary": "Mobile, Alabama • Greenbrae, California • Whittier, California + 27 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04109066"
    },
    {
      "nct_id": "NCT00002302",
      "title": "The Safety and Effectiveness of r-HuEPO in Patients With AIDS and Anemia Caused by AIDS and Treatment With AZT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections",
        "Cytopenias"
      ],
      "interventions": [
        {
          "name": "Epoetin alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ortho Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-04T08:34:53.483Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Raritan, New Jersey",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Raritan",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002302"
    }
  ]
}